PHARMACY

Wyeth, Osmotica settle Effexor patent case

BY Drew Buono

MADISON, N.J. Wyeth has settled a patent-infringement case with Osmotica Pharmaceuticals over its antidepressant drug Effexor XR, according to published reports.

Under the terms of the deal Osmotica will pay royalties to Wyeth on some of its patents in exchange for launching a generic version of the drug’s extended-release version. The drug though will not be an exact copy of the drug because it will be available in a tablet not capsule form like Sun Pharmaceuticals generic version.

The two companies are launching a tablet form in hopes of getting into the multi-billion dollar sales of the drug sooner. The major patent for Effexor expires in June, but the capsule patent expires much later, so the companies are using this to their advantage. Pharmacists though won’t be able to simply generically substitute this medication for Effexor unlike other generic versions of drugs.

Effexor generated sales of $3.8 billion last year, making it Wyeth’s biggest selling drug.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

ScriptPro robotic dispensing adopted in two Haggen locations

BY Drew Buono

BELLINGHAM, Washington Haggen Food & Pharmacy has added ScriptPro’s robotic dispensing devices to two of its stores, one in Ferndale and the other in Barkley Village, according to published reports.

The system automatically selects a prescription vial, counts tablets or capsules into the vial and labels it with patient, drug and dosing information.

“This system offers many advantages for our customers,” said Andrew Charter, vice president of pharmacy at Haggen Inc. “It is better than partially automated systems in providing accurately counted doses. Most importantly, it frees up our pharmacists to spend more time answering the questions of customers rather than counting pills or making labels.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Eli Lilly, Sanofi-Aventis partner to market Cialis

BY Drew Buono

BRDIGEWATER, N.J. Sanofi-Aventis has agreed to help Eli Lilly market its impotency drug Cialis, according to CNN. Financial terms were not disclosed.

Lilly gained full rights to the medicine at the beginning of 2007, when it bought the drug from ICOS for $2.3 billion.

Cialis had worldwide sales of $1.1 billion in 2007, compared with its main competitor Pfizer’s Viagra, which saw sales of $1.76 billion.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?